Gilead begins PhI trial of inhaled remdesivir
The inhaled formulation is being assessed for COVID-19 patients in the outpatient setting
Read More
Tag: inhalable
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
- CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
- FDA approves new high dose Spinraza regimen for SMA
